Key TakeawaysA three-year study of tirzepatide—the active ingredient in Eli Lilly's injectable weight-loss drug Zepbound and diabetes treatment Mounjaro—showed a 94% reduction in type 2 diabetes progression risk compared to a placebo.Patients who received tirzepatide lost 22.9% of their body weight on average, compared with 2.1% for patients who received a placebo.Eli Lilly shares jumped to an all-time high on Tuesday, bringing their year-to-date return to more than 60%. Eli Lilly (LLY) stock jumped to a re ...

By clicking “Sign Up”, you accept our Terms of Service and Privacy Policy . You can opt-out at any time by visiting our Preferences page or by clicking "unsubscribe" at the bottom of the email.Access your favorite topics in a personalized feed while you're on the go. download the appThanks for signing up! Go to newsletter preferencesSign up to get the inside scoop on today’s biggest stories in markets, tech, and business — delivered daily. Read previewFirst, these new injectable drugs were meant to treat di ...

Eli Lilly And Co (NYSE:LLY) announced today preliminary results from a late-stage study indicated the main ingredients Zepbound and Mounjaro of weight-loss drug tirzepatide reduced the risk of progression to type 2 diabetes by 94%. Additionally, patients saw weight reduction of about 15% to 23%, depending on drug dosage.In response, LLY is up 2.4% to trade at $943.22 at last check. The shares are bouncing off a pullback from a July 15, record high of $966.10 to the $740 region, with a newfound floor at the ...

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024.Eli Lilly's highly popular weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with pre-diabetes compared to a placebo, according to initial results from a long-term study released on Tuesday. The late-stage trial on tirzepatide, the active ingredient in the company's weight loss injection Zepbound and diabetes drug Mounjaro, also found that ...

176-week SURMOUNT-1 Phase 3 study in adults with pre-diabetes is the longest completed trial of tirzepatide to date Tirzepatide resulted in sustained weight loss through the treatment period, averaging a 22.9% decrease in body weight with the 15 mg dose at end of treatmentResults are consistent with the combined pharmacology of GIP and GLP-1 receptor agonismINDIANAPOLIS, Aug. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today positive topline results from the SURMOUNT-1 three-year st ...

A year ago, medical experts and Nobel Laureates interviewed by The New York Times proclaimed "a Golden Age of Medicine" is here.And in the 12 months since, a flurry of new drug and medical discoveries has proven them to be right.From new cancer treatment breakthroughs, to the first-ever FDA-approved genetic editing treatment for illness, new medical advances are helping to cure millions of people from diseases that used to stump scientists.And in the process, the "Golden Age of Medicine" has lit a fire unde ...

Impediments to growth are melting away while new opportunities begin to rise.Eli Lilly (LLY -1.01%) and Novo Nordisk (NVO -1.58%) give new meaning to the word "unstoppable" in the context of pharma stocks. Whereas the total return of Lilly's shares soared by 245% over the last three years, Novo Nordisk's rose by 165%, meaning that both easily beat the broader market's growth of just 25%.There's little indication that either company is about to slow down significantly, even in the face of a couple of headwin ...

Eli Lilly has a lot going for it.Over the last couple of years, the pharmaceutical industry has been taken over by glucagon-like peptide-1 (GLP-1) agonists. Even if you aren't familiar with that terminology, I'd wager that you're well aware of diabetes and obesity medications such as Ozempic, Wegovy, and Mounjaro -- which are all GLP-1 drugs.For now, Denmark-based Novo Nordisk (NVO -1.58%) dominates the GLP-1 market, thanks to its deep roster of treatments including Ozempic, Wegovy, Rybelsus, and Saxenda. H ...

There's no stopping this incredible pharmaceutical stock.Companies worth more than $1 trillion are a rare breed, at least for now. Many more corporations will join this elusive group in the coming years and decades. And the next one to accomplish this feat might be Eli Lilly (LLY -1.01%).The pharmaceutical giant is one of the closest to a $1 trillion market cap among those companies closing in on that milestone. Here is why the drugmaker could beat out its competitors and continue growing long after.Will va ...

These stocks should keep up their winning ways.The recent stock market sell-off appears to have fizzled out and now could be a great time for long-term investors to put some of their cash to work.Three Motley Fool contributors think they've found fantastic growth stocks to buy in August. Here's why they picked Eli Lilly (LLY -1.01%), Novo Nordisk (NVO -1.58%), and Vertex Pharmaceuticals (VRTX 1.14%).A behemoth that could double in sizeDavid Jagielski (Eli Lilly): Growth investors might be tempted to look fo ...